During the past decade, Ambulantes Krebszentrum Hamburg conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ambulantes Krebszentrum Hamburg" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Ambulantes Krebszentrum Hamburg" are "NSCLC" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Non-small Cell Lung Cancer" (1 trials) and "Non-squamous NSCLC" (1 trials). Many other conditions were trialed in "Ambulantes Krebszentrum Hamburg" in a lesser frequency.

Most popular intervention types in "Ambulantes Krebszentrum Hamburg" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Afatinib" (1 trials), "Brigatinib" (1 trials), "Ociperlimab" (1 trials), "Osimertinib" (1 trials) and "PF-02341066" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ambulantes Krebszentrum Hamburg" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Ambulantes Krebszentrum Hamburg". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Ambulantes Krebszentrum Hamburg, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ambulantes Krebszentrum Hamburg, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".